Nurse Practitioner Program year 2024 Reported 2021–2024 Source: CMS Open Payments, 2026 publication

Amy Stratton

Nurse Practitioner, Psychiatric/Mental Health Grand Rapids, MI Nurse Practitioner

NPI 1124494539 CMS profile 11176734

790 Fuller Ave Ne, Grand Rapids, MI 49503

Open in the dashboard

General payments

$7,125

427 records reported · program years 2021–2024

Research payments

$0

Paid to them · None reported · program years 2021–2024

Ownership & investment interest

$0

None reported

Through program year 2024, Amy Stratton of Grand Rapids, MI is reported in the CMS Open Payments database as having received $7,125 across 427 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Psychiatric/Mental Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

4 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $911 37
2023 General $1,950 140
2022 General $1,887 108
2021 General $2,376 142

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amy Stratton
  • Nurse Practitioner, Psychiatric/Mental Health median
  • Middle half of Nurse Practitioner, Psychiatric/Mental Health
  • National median

In program year 2025, general payments to Amy Stratton were reported at $0. Among 26,152 Nurse Practitioner, Psychiatric/Mental Health profiles paid that year, the median was $258 and the middle half received between $93 and $764.

Show as a table
Year Amy Stratton Nurse Practitioner, Psychiatric/Mental Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,376 $166 $54–$482 $132
2022 $1,887 $195 $66–$559 $149
2023 $1,950 $233 $82–$673 $160
2024 $911 $236 $84–$688 $164
2025 $0 $258 $93–$764 $169

Breakdown

Who paid General payments · program years 2021–2024
  1. AbbVie, Inc. $1,069 88 payments
  2. ITI, Inc. $914 47 payments
  3. Teva Pharmaceuticals USA, Inc. $755 43 payments
  4. Supernus Pharmaceuticals, Inc. $738 48 payments
  5. Otsuka America Pharmaceutical, Inc. $633 28 payments
  6. Janssen Pharmaceuticals, Inc $557 20 payments
  7. Lundbeck LLC $520 35 payments
  8. Neurocrine Biosciences, Inc. $495 28 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $409 33 payments
  10. Alkermes, Inc. $369 18 payments
  11. Other $665 39 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2024
  1. Food and Beverage $7,125 427 payments
Products named General payments · program years 2021–2024
  1. VRAYLAR $1,069 88 payments
  2. CAPLYTA $914 47 payments
  3. REXULTI Psychiatry $489 26 payments
  4. REXULTI Psychiatry $481 33 payments
  5. QELBREE $460 40 payments
  6. AUSTEDO $454 31 payments
  7. TRINTELLIX $409 33 payments
  8. SPRAVATO $362 11 payments
  9. ARISTADA Cns $299 15 payments
  10. ARISTADA Cns $299 15 payments
  11. Other $3,648 179 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 38 drugs

Part D claims

1,116

Median for Nurse Practitioner: 389

Drug cost

$85,113

Median for Nurse Practitioner: $21,885

Branded share of claims

24.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Invega Sustenna Paliperidone Palmitate Brand 11 $38,426
Vraylar Cariprazine Hcl Brand 11 $15,107
Trintellix Vortioxetine Hydrobromide Brand 14 $8,505
Lurasidone Hcl Generic 16 $3,716
Vilazodone Hcl Generic 13 $3,375
Duloxetine Hcl Generic 38 $1,062
Quetiapine Fumarate Generic 71 $999
Olanzapine Generic 39 $985
Bupropion Xl Bupropion Hcl Brand 36 $975
Lamotrigine Generic 73 $957

The 10 drugs with the highest cost, of 38 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qelbree
  • Supernus Pharmaceuticals, Inc. $278
$278 — —
VRAYLAR
  • AbbVie, Inc. $155
$155 11 —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $117
$117 — —
REXULTI
  • Lundbeck LLC $65
  • Otsuka America Pharmaceutical, Inc. $10
$75 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $55
$55 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

427 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Psychiatric/Mental Health in Michigan

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record